A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer responsible for batch release
- Tamiflu - oseltamivir
Prescription drugs listed. Substance: "Oseltamivir"
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal products subject to medical prescription
- Topotecan actavis - Actavis Group PTC ehf
- Levetiracetam actavis - Actavis Group PTC ehf
- Glidipion (pioglitazone actavis group) - Actavis Group PTC ehf
- Telmisartan actavis - Actavis Group PTC ehf
- Levetiracetam actavis group - Actavis Group PTC ehf
Prescription drugs listed. Manufacturer: "Actavis Group PTC ehf"
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Periodic safety update reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
- Tamiflu - J05AH02
Prescription drugs listed. ATC Code: "J05AH02"
Risk Management Plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
At the request of the European Medicines Agency;
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.